About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AMGN - Amgen Inc.| Previous Close | $258.78 | Open | |
| Volume | 276 | Market Cap | 147.238B |
| Yield | 2.54 % | Last Dividend | $6.49 |
| Amgen's Bemarituzumab Scores Breakthroug... | 04/20/21 |
| The FDA has granted Breakthrough Therapy Designation to Amgen Inc's (NASDAQ: AMGN ) bemarituzumab for patients with gastric and gastroesophageal (GEJ)... | |
| Citius Thrives in 2021 with Critical Car... | 04/19/21 |
| The following article is sponsored by Citius Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or... | |
| Is Silicon Valley Replacing Big Pharma I... | 04/06/21 |
| The following article is sponsored by Mind Cure. The information contained in this article in no way represents investment advice or opinion on the pa... | |
| The Latest Picks And Pans From Barron's:... | 04/04/21 |
| This weekend's Barron's cover story discusses a beleaguered social media giant that is still a buy. Other featured articles share infrastructure picks... | |
| BioNTech Stock Has Surged on Covid Vacci... | 04/02/21 |
| CEO Ugur Sahin says his goal has been to make the biotech the next Amgen or Genentech. | |
| Oppenheimer Stick to Their Buy Rating fo... | 03/29/21 |
| Oppenheimer Stick to Their Buy Rating for Amgen Inc | |
| Eliem Therapeutics Emerges from Stealth ... | 03/25/21 |
| SEATTLE and CAMBRIDGE, England, March 25, 2021 /PRNewswire/ -- Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live ... | |
| Blinatumomab: An Investigational BiTE An... | 03/23/21 |
| DUBLIN--(BUSINESS WIRE)--The "Blinatumomab - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. ... | |
| AI IN HEALTHCARE ADMINISTRATION: How dig... | 03/23/21 |
| Summary List Placement Insider Intelligence publishes thousands of research reports, charts, and forecasts on the Digital Health industry. You can lea... | |
| Though Potential Bidders Moved Away, Amg... | 03/19/21 |
| Earlier this month, biotech giant Amgen Inc (NASDAQ: AMGN ) announced a $1.9 billion buyout of Five Prime Therapeutics Inc (NASDAQ: FPRX ) that outlas... | |
| Outbidding 14 others and then themselves... | 03/19/21 |
| In the summer of 2020, you could get a share of Five Prime Therapeutics for less than a latte, but the company's leadership knew that could soon chang... | |
| Therapeutic Proteins and Oral Vaccines M... | 03/19/21 |
| Therapeutic proteins can be used to replace a protein that is abnormal or deficient in a particular disease. They can also augment the body???s supply... | |
| MENA Biologics & Biosimilars Market Majo... | 03/18/21 |
| MENA Biologics & Biosimilars Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and ... | |
| Innovative Report on Adalimumab Biosimil... | 03/18/21 |
| The exclusive research report on the Global Adalimumab Biosimilar Market 2021 examines the market in detail along with focusing on significant market ... | |
| Laryngeal Cancer Therapeutics Market To ... | 03/18/21 |
| The global laryngeal cancer therapeutics market is expected to grow by $635.07 million during 2021-2025 helped by Amgen Inc (NASDAQ: AMGN ) and AstraZ... | |
| Laryngeal Cancer Therapeutics Market to ... | 03/17/21 |
| NEW YORK, March 17, 2021 /PRNewswire/ ??? The global laryngeal cancer therapeutics market is expected to grow by USD 635.07 million during 2021-2025, ... | |
| 3 Biotech Stocks That Could Double In 12... | 03/17/21 |
| Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and ana... | |
| Biosimilar Pipeline Analysis Market | Bi... | 03/17/21 |
| Biosimilar Pipeline Analysis Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and ... | |
| Immunotherapy Drugs Market | GlaxoSmithK... | 03/17/21 |
| Immunotherapy Drugs Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional ... | |
| Orphan Drugs Market | Acorda Therapeutic... | 03/17/21 |
| Orphan Drugs Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth ... | |
| Biopharmaceuticals and Biomedicine Marke... | 03/15/21 |
| Biopharmaceuticals and Biomedicine Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation... | |
| Global Leukemia Therapeutics Market by M... | 03/15/21 |
| Leukemia Therapeutics Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regio... | |
| Barron's Latest Picks And Pans: Apple, C... | 03/13/21 |
| This weekend's Barron's cover story discusses how the U.S. economy could soar as the pandemic fades. Other featured articles discuss why big pharmaceu... | |
| FIVE PRIME INVESTOR ALERT by the Former ... | 03/11/21 |
| NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (???KSF???) a... | |
| Amgen To Present At The Oppenheimer 31st... | 03/11/21 |
| THOUSAND OAKS, Calif., March 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at... | |
| FXNEWS24 |Biotech Stock Roundup: AMGN's ... | 03/10/21 |
| Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News | |
| Amgen buying Five Prime in $1.9B bid to ... | 03/09/21 |
| Lured by what Amgen Inc. CEO Bob Bradway called a "compelling opportunity" to strengthen the Thousand Oaks, Calif.-based company's oncology portfolio ... | |
| The Week Ahead In Biotech (March 7-13): ... | 03/06/21 |
| Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did ... | |
| Multiple Myeloma Drugs Market Trends Sho... | 03/05/21 |
| The global Multiple Myeloma Drugs market size is projected to grow from 2021 to 2026. The demand for Multiple Myeloma Drugs can be attributed to patie... | |
| Five Prime Therapeutics (FPRX) Stock Jum... | 03/05/21 |
| Stocks Analysis by Zacks Investment Research covering: Amgen Inc, Five Prime Therapeutics Inc. Read Zacks Investment Research's latest article on Inve... | |
| Strong Buy rating | 04/19/21 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $279.00 to $281.00 | |
| Strong Buy rating | 04/05/21 |
| Oppenheimer maintains Outperform rating and raises Price Target from $266.00 to $275.00 | |
| Buy rating | 03/05/21 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $252.00 to $260.00 | |
| Strong Buy rating | 03/05/21 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $277.00 to $279.00 | |
| Hold rating | 03/05/21 |
| Barclays maintains Equal-Weight rating and lowers Price Target from $242.00 to $230.00 | |
| Buy rating | 03/01/21 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $245.00 to $252.00 | |
| Buy rating | 02/03/21 |
| SVB Leerink maintains Market Perform rating and lowers Price Target from $253.00 to $245.00 | |
| Strong Buy rating | 02/03/21 |
| Piper Sandler maintains Overweight rating and lowers Price Target from $280.00 to $260.00 | |
| Strong Buy rating | 02/03/21 |
| Morgan Stanley maintains Overweight rating and lowers Price Target from $285.00 to $277.00 | |
| Strong Buy rating | 02/03/21 |
| Credit Suisse maintains Outperform rating and lowers Price Target from $280.00 to $265.00 | |
| Strong Buy rating | 02/03/21 |
| Cantor Fitzgerald maintains Overweight rating and raises Price Target from $280.00 to $295.00 | |
| Date | 2021-02-02 (AMC) | Est. (EPS/Rev.) | $3.39/ 6.58B |
| Actual (EPS/Rev.) | $3.81/ $6.63 B | EPS (TTM) | 12.84 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech Trades | Tech Trades | 81.00 % | Follow |
| Options Eagle | George | 78.00 % | Follow |
| Anti Analysts | Chen Capital | 76.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Earnings plays | Chen Capital | 65.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
